Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07587853

Genetic Variants in Idiopathic Premature Ovarian Insufficiency

Premature ovarian insufficiency is a condition in which ovarian function decreases or is lost before the age of 40 years. In many patients, the underlying cause remains unexplained. This prospective observational case-control study aims to investigate pathogenic and likely pathogenic genetic variants in DNA repair and meiotic genes related to ovarian reserve and folliculogenesis in women with idiopathic premature ovarian insufficiency.

The study will include women younger than 40 years with idiopathic premature ovarian insufficiency and age- and ethnicity-matched control participants with normal ovarian function. Clinical and reproductive data will be collected, and a peripheral blood sample will be obtained from each participant for whole exome sequencing. The frequency of pathogenic or likely pathogenic variants will be compared between the case and control groups. No investigational drug, device, or treatment intervention will be administered.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Premature Ovarian Insufficiency Adnexal Diseases Endocrine System Diseases Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Genital Diseases Genital Diseases, Female Gonadal Disorders Ovarian Diseases Primary Ovarian Insufficiency Urogenital Diseases

Age range

18 year–39 year

Sex eligibility

Female

Study type

Observational

Primary location

University of Health Sciences Tepecik Training and Research Hospital, Department of Obstetrics and Gynecology

Bornova, İzmir, 35100, Turkey (Türkiye)

Location contact

Çağlasu Sancaktar, MD

CONTACT

[email protected]

+90 507 258 3948

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

For the idiopathic premature ovarian insufficiency group:

  • Women aged 18 to 39 years.
  • Spontaneous amenorrhea or marked menstrual irregularity lasting at least 4 months.
  • Serum FSH level greater than 25 IU/L. In cases of diagnostic uncertainty, FSH measurement may be repeated after 4 to 6 weeks.
  • Diagnosis of idiopathic premature ovarian insufficiency, with no known chromosomal abnormality, FMR1 premutation, defined syndromic genetic diagnosis, or iatrogenic cause.
  • Willingness to participate in the study and ability to provide written informed consent.

For the control group:

  • Women aged 18 to 39 years.
  • Regular menstrual cycles.
  • Age-appropriate normal ovarian reserve findings, including FSH and AMH values within age-appropriate reference ranges and, when available, appropriate antral follicle count.
  • No known history of infertility, premature ovarian insufficiency, or early menopause.
  • No history of gonadotoxic treatment or ovarian surgery.
  • Willingness to participate in the study and ability to provide written informed consent.

Exclusion criteria

For both groups:

  • Known chromosomal abnormality, such as Turner syndrome or structural X chromosome abnormality.
  • FMR1 premutation carrier status.
  • Previously defined syndromic genetic diagnosis.
  • Active malignancy.
  • History of gonadotoxic chemotherapy or pelvic radiotherapy.
  • Iatrogenic ovarian damage or iatrogenic premature ovarian insufficiency after ovarian surgery.
  • Clear autoimmune, endocrine, or other clinical condition that may explain secondary amenorrhea.
  • Refusal to provide informed consent or request to withdraw study data.
  • Insufficient DNA sample quality or inability to complete genetic analysis for technical reasons.

Additional exclusion criteria for the control group:

  • Known history of infertility, premature ovarian insufficiency, or early menopause.
  • Ovarian reserve findings below the expected range for age.
  • Previous gonadotoxic treatment or ovarian surgery.

Treatment and study plan

Primary outcomes

  1. Prevalence of Pathogenic or Likely Pathogenic Variants in the Target Gene Set

    Time frame: Through study completion, up to 24 months

    Proportion of participants in each group who carry pathogenic or likely pathogenic variants, classified according to ACMG/AMP criteria, in the predefined 57-gene target set related to ovarian reserve, folliculogenesis, DNA repair, and meiosis.

Study contacts

Contact information is provided by the study sponsor or research team.

Çağlasu Sancaktar, MD

CONTACT

[email protected]

+90 507 258 3948

Sponsors and collaborators

Lead sponsor

Abdurrahman Hamdi İnan

Other

Registry information

Official study title

Investigation of Pathogenic Variants in DNA Repair and Meiotic Genes Associated With Ovarian Reserve and Folliculogenesis in Idiopathic Premature Ovarian Insufficiency Using Whole Exome Sequencing: A Case-Control Study

Important dates

Study start
2026
Primary completion
2028
Study completion
2028
First posted
May 14, 2026
Registry last updated
May 19, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.